Clinical trials
Advanced Tumors clinical trials
Below are recruiting advanced tumors clinical trials, each written for real people, not researchers. We’re tracking 1,346 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07595237RecruitingEarly Phase 1
Radioactive treatment for advanced solid tumors with Claudin18.2
This early-stage trial tests a new radioactive drug (177Lu-DOTA-SNA040) designed to target a protein called Claudin18.2 found on certain cancer cells. The drug delivers radiation directly to tumors in patients with advanced gastric, pancreatic, or bile duct cancers that have stopped responding to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06912152RecruitingPhase 1
Testing MT027 for advanced belly-lining cancers
This trial tests an experimental intraperitoneal therapy (MT027) for people whose advanced solid tumors have spread to the lining of the belly (peritoneum) and haven't responded to standard treatments. It aims to see if this new approach can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–70 - NCT06707610RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called ALK202 for people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and to find the best dose.
Margate, FloridaAges 18–75 - NCT06302062RecruitingPhase 1
Using lymph node T cells for advanced solid tumors
This trial tests a new treatment using T cells taken from your lymph nodes to fight advanced solid tumors that have not responded to standard therapies. The goal is to see if this approach can help shrink tumors or slow their growth.
Guangzhou, GaungdongAges 18–75 - NCT06245122RecruitingPhase 1
Study of CS23546 for advanced tumors
This trial tests a new drug called CS23546 for people with advanced solid tumors or lymphoma that have not responded to other treatments. Researchers will check your tumor for certain markers (PD-L1 and MSI) to see if the drug might work for you.
GuangzhouAges 18 years+ - NCT07524140RecruitingPhase 1
Study of ZE94-0605 for advanced solid tumors
This trial tests a new drug called ZE94-0605 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and can shrink tumors.
Kogarah, New South WalesAges 18 years+ - NCT04145622RecruitingPhase 1/Phase 2
Ifinatamab deruxtecan for advanced hard-to-treat solid cancers
This early-stage trial tests an investigational antibody-drug medicine (ifinatamab deruxtecan) in people with advanced solid tumors. It aims to see whether it can shrink tumors or help control cancer, and to learn about side effects and the best way to use it.
Los Angeles, CaliforniaAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Irvine, CaliforniaAges 12 years+ - NCT04785196RecruitingPhase 1/Phase 2
Testing an MDM2 drug plus an immune therapy for advanced tumors
This trial tests APG-115 together with a PD-1 immune therapy in people with advanced liposarcoma or other advanced solid tumors. It may help by blocking tumor growth through a mix of direct tumor targeting and immune system activation.
Guangzhou, GuangdongAges 18 years+ - NCT04924075RecruitingPhase 2
Belzutifan for cancers linked to VHL or HIF-2α changes
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
Los Angeles, CaliforniaAges 12 years+ - NCT04977453RecruitingPhase 1/Phase 2
Study drug GI-101 alone or with immune or blood-pressure meds
This early-phase study tests GI-101 in people with advanced solid cancers. It may be given alone or combined with pembrolizumab or lenvatinib to see how safe it is and whether it can shrink tumors.
New York, New YorkAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Tucson, ArizonaAges 18 years+ - NCT05269316RecruitingPhase 1/Phase 2
Early-phase study of IMP9064 for advanced solid tumors
This Phase 1/2 trial tests IMP9064, either alone or with another treatment, in people with advanced solid cancers that have stopped responding to standard care. It aims to see how well it works and how safe it is, including whether it can be used when treatment options are limited.
Hackensack, New JerseyAges 18 years+ - NCT05315167RecruitingPhase 1/Phase 2
Study drug PRJ1-3024 for advanced solid tumors
This trial tests how safe PRJ1-3024 is and how the body handles it, and it also looks for early signs that it can shrink advanced solid tumors. It may help people whose cancer can’t be treated with standard options.
Zhengzhou, HenanAges 18 years+ - NCT05525858Recruiting
Genomic testing–guided treatment for advanced solid tumors
This study uses your tumor’s genetic test results to help match you to the most suitable treatment when standard options have failed or don’t exist. It may help by targeting therapies based on specific gene changes found in your cancer.
Bucheon-siAges 19 years+ - NCT05661461RecruitingPhase 1
Test drug dosing and safety for advanced cancers with liver issues
This Phase 1 study tests different doses of nab-sirolimus to see if it is safe and how the body processes it. It is for people with advanced or metastatic solid tumors who also have moderate liver impairment.
San Antonio, TexasAges 18 years+ - NCT05867251RecruitingPhase 1/Phase 2
AVZO-021 for advanced breast and ovarian cancers
This early-stage study tests AVZO-021, a new anti-cancer medicine, in people with advanced solid tumors like specific types of breast and ovarian (or related) cancers. It’s meant to find the safest dose and look for signs the medicine can shrink tumors, especially in cancers with certain gene changes.
New Haven, ConnecticutAges 18 years+ - NCT05969860RecruitingPhase 2
Home cancer treatment vs clinic treatment for advanced cancer
This Phase 2 trial compares giving certain standard cancer infusions at home versus in a clinic. It may help people avoid clinic visits while still receiving the same cancer treatment safely.
Jacksonville, FloridaAges 18 years+ - NCT06028724Recruiting
Looking for cancer mutations using a blood test
This study uses a blood test (liquid biopsy) to find genetic changes in advanced solid tumors. It may help doctors choose the right treatment and monitor how well it works over time.
Aviano, PordononeAges 18 years+ - NCT06112704RecruitingPhase 2
HS-20093 for advanced esophageal and other solid tumors
This trial tests an investigational drug called HS-20093 for people with advanced esophageal cancer or other solid tumors that have not responded to prior treatment. The drug targets a protein on cancer cells called B7-H3, and the study aims to see if it can shrink tumors or slow their growth.
Hefei, AnhuiAges 18 years+ - NCT06120283RecruitingPhase 1
Testing a new drug for breast cancer and other solid tumors
This trial tests a new oral drug (BGB-43395) alone or with other treatments for people with advanced breast cancer or other solid tumors that depend on CDK4. It aims to find safe doses and see if the drug helps shrink tumors or slow growth.
Denver, ColoradoAges 18 years+ - NCT06171750RecruitingPhase 1
Study of ANK-101 for advanced solid tumors
This trial tests a new drug, ANK-101, injected directly into tumors to help fight advanced solid tumors that have spread or can't be treated with standard therapies. It may be an option if you have a tumor that can be reached for injection.
Bethesda, MarylandAges 18 years+ - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Los Angeles, CaliforniaAges 18 years+ - NCT06302621RecruitingPhase 1
Pemigatinib plus afatinib for advanced solid tumors with FGFR changes
This trial tests two targeted drugs, pemigatinib and afatinib, together for people with advanced solid tumors that have a specific FGFR genetic change. It may be an option if standard treatments have stopped working or aren't available.
Boston, MassachusettsAges 18 years+
Hear when a new Advanced Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced tumors?
- Yes. Clin2 currently lists 1,346 recruiting advanced tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Advanced or Metastatic Solid Tumors
- Locally Advanced or Metastatic Solid Tumors
- Advanced Malignant Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.